S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:OPTN

OptiNose (OPTN) Stock Forecast, Price & News

$1.94
-0.02 (-1.02%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.89
$1.98
50-Day Range
$1.76
$2.70
52-Week Range
$1.46
$3.85
Volume
43,785 shs
Average Volume
142,186 shs
Market Capitalization
$160.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.47
30 days | 90 days | 365 days | Advanced Chart
Receive OPTN News and Ratings via Email

Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter.

OptiNose logo

About OptiNose

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Headlines

OptiNose (OPTN) Scheduled to Post Earnings on Thursday
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OPTN
Fax
N/A
Employees
189
Year Founded
N/A

Sales & Book Value

Annual Sales
$74.65 million
Book Value
($0.54) per share

Profitability

Net Income
$-82.30 million
Net Margins
-105.32%
Pretax Margin
-105.32%

Debt

Price-To-Earnings

Miscellaneous

Free Float
77,720,000
Market Cap
$160.40 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/12/2022
Today
5/21/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.15 out of 5 stars

Medical Sector

432nd out of 1,416 stocks

Pharmaceutical Preparations Industry

181st out of 677 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













OptiNose (NASDAQ:OPTN) Frequently Asked Questions

Is OptiNose a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OptiNose stock.
View analyst ratings for OptiNose
or view top-rated stocks.

When is OptiNose's next earnings date?

OptiNose is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for OptiNose
.

How were OptiNose's earnings last quarter?

OptiNose, Inc. (NASDAQ:OPTN) posted its quarterly earnings data on Thursday, May, 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.04. During the same quarter last year, the business posted ($0.49) earnings per share.
View OptiNose's earnings history
.

What guidance has OptiNose issued on next quarter's earnings?

OptiNose issued an update on its FY 2022 earnings guidance on Thursday, May, 19th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $90.00M-, compared to the consensus revenue estimate of $98.82 million.

What price target have analysts set for OPTN?

2 brokerages have issued 12-month price objectives for OptiNose's shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate OptiNose's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 363.9% from the stock's current price.
View analysts' price targets for OptiNose
or view top-rated stocks among Wall Street analysts.

Who are OptiNose's key executives?
OptiNose's management team includes the following people:
What other stocks do shareholders of OptiNose own?
When did OptiNose IPO?

(OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.

What is OptiNose's stock symbol?

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

Who are OptiNose's major shareholders?

OptiNose's stock is owned by a number of institutional and retail investors. Top institutional investors include Bleichroeder LP (4.53%), Velan Capital Investment Management LP (2.42%), Vanguard Group Inc. (2.29%), Massachusetts Financial Services Co. MA (2.16%), Rice Hall James & Associates LLC (1.07%) and BlackRock Inc. (0.93%). Company insiders that own OptiNose stock include Joseph C Scodari, Keith A Goldan, Keith A Goldan, Michael F Marino III, Michael F Marino III, Peter K Miller, Peter K Miller, Ramy A Mahmoud, Ramy A Mahmoud and Victor M Clavelli.
View institutional ownership trends for OptiNose
.

Which institutional investors are selling OptiNose stock?

OPTN stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., and Simplex Trading LLC. Company insiders that have sold OptiNose company stock in the last year include Keith A Goldan, Michael F Marino III, Peter K Miller, Ramy A Mahmoud, and Victor M Clavelli.
View insider buying and selling activity for OptiNose
or view top insider-selling stocks.

Which institutional investors are buying OptiNose stock?

OPTN stock was purchased by a variety of institutional investors in the last quarter, including Velan Capital Investment Management LP, Assenagon Asset Management S.A., State Street Corp, Prelude Capital Management LLC, Jane Street Group LLC, Massachusetts Financial Services Co. MA, Northern Trust Corp, and Easterly Investment Partners LLC. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Keith A Goldan, Michael F Marino III, Peter K Miller, and Victor M Clavelli.
View insider buying and selling activity for OptiNose
or or view top insider-buying stocks.

How do I buy shares of OptiNose?

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptiNose's stock price today?

One share of OPTN stock can currently be purchased for approximately $1.94.

How much money does OptiNose make?

OptiNose has a market capitalization of $160.40 million and generates $74.65 million in revenue each year. The company earns $-82.30 million in net income (profit) each year or ($1.30) on an earnings per share basis.

How many employees does OptiNose have?

OptiNose employs 189 workers across the globe.

What is OptiNose's official website?

The official website for OptiNose is www.optinose.com.

How can I contact OptiNose?

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at (267) 364-3500 or via email at [email protected].

This page was last updated on 5/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.